Naloxone methiodide is a quaternary ammonium derivative of naloxone, primarily known for its role as an opioid antagonist. It is characterized by its ability to cross the blood-brain barrier less effectively than naloxone itself due to its quaternary structure, which makes it more polar and less lipophilic. This property allows naloxone methiodide to be used in research settings to study opioid receptor interactions without affecting central nervous system activity. The substance is typically presented as a white to off-white solid and is soluble in water and other polar solvents. Its mechanism of action involves competitive inhibition at opioid receptors, particularly the mu-opioid receptor, thereby reversing the effects of opioid overdose. Naloxone methiodide is often utilized in pharmacological studies to explore the pharmacodynamics of opioids and their antagonists, contributing to the understanding of opioid addiction and treatment strategies. Safety and handling precautions are essential, as with all chemical substances, to mitigate any potential risks associated with its use.

Naloxone methiodide

93302-47-7: Naloxone methyliodide, N-Methylnaloxonium iodide, Morphinanium, 4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-17-(2-propenyl)-, iodide, (5α,17R)-, Naloxone methiodide, Morphinanium, 4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-17-(2-propen-1-yl)-, iodide (1:1), (5α,17R)-

Naloxone methiodide is a microdialysis probe that blocks the effects of opioids, such as morphine and codeine. It is a competitive antagonist of κ-opioid receptors and has been shown to be effective in reducing locomotor activity in rats with chronic pain. Naloxone methiodide has also been shown to block the binding of kappa-opioid receptors by naloxone. This drug has been used in vivo as a model for bowel disease, myocardial infarct, and small-molecule drug testing.

CAS 93302-47-7: Naloxone methiodide

Naloxone methiodide

Ref: 7W-GP7789

Naloxone methiodide

Ref: 3D-TDA30247